Clinical Trial Update: Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the VX-121/Tezacaftor/Deutivacaftor combination in children with cystic fibrosis aged 1 through 11 years is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• VX-121/Tezacaftor/Deutivacaftor

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: RECRUITING